ArticleCirculation reports2026
Pharmacy-Based Atrial Fibrillation Screening Model Coordinated by a Regional Stroke and Cardiovascular Disease Support Center: The Catch AF Project.
Article in Circulation reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrillation (AF) is a major cause of cardioembolic stroke and often remains undiagnosed because of its asymptomatic or paroxysmal nature. Although opportunistic AF screening has been advocated, sustainable community-based screening models that link the results to medical evaluations are limited. We implemented a pharmacy-based AF screening initiative (Catch AF project) led by a regional Stroke and Cardiovascular Disease Support Center with community pharmacists and physicians to assess its feasibility and follow-up outcomes. Methods and Results: The Catch AF project was conducted at 34 community pharmacies in Nagasaki, Japan. A single-lead electrocardiogram (ECG) device with automated analysis was installed to offer opportunistic screening for pharmacy visitors. Of the 5,371 ECG recordings, 123 (2.29%) indicated possible AF. Pharmacists recommended medical consultation for 60 individuals (49% of the detected cases). Questionnaire surveys demonstrated that stakeholders generally perceived the initiative as acceptable and feasible. In contrast, only a small number of physicians reported encounters with referred patients, indicating a marked gap between AF detection through pharmacy-based screening and subsequent medical evaluation. Conclusions: A center-led pharmacy-based AF screening initiative is feasible and well accepted in a real-world setting. However, a substantial gap between screening detection and clinical follow up highlights the need for improved referral pathways and coordination between pharmacies and medical institutions to enhance the effectiveness of community-based screening programs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.